Erik A. Dahm

Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Daratumumab-EPOCH for transformed anaplastic multiple myeloma.

Daratumumab-EPOCH for transformed anaplastic multiple myeloma.

Journal: Hematology, transfusion and cell therapy

Published: March 04, 2025

Effect of drug interactions with apixaban on clinical outcomes in cancer patients with venous thromboembolism.

Effect of drug interactions with apixaban on clinical outcomes in cancer patients with venous thromboembolism.

Journal: Frontiers in oncology

Published: October 31, 2024

Exercise capacity, dyspnea, and quality of life 6 months after exercise-based rehabilitation in patients with persistent dyspnea following pulmonary embolism.

Exercise capacity, dyspnea, and quality of life 6 months after exercise-based rehabilitation in patients with persistent dyspnea following pulmonary embolism.

Journal: Research and practice in thrombosis and haemostasis

Published: October 15, 2024

Treatment of older patients with acute myelogenous leukaemia without allogenic stem cell transplantation at Akershus University Hospital

Treatment of older patients with acute myelogenous leukaemia without allogenic stem cell transplantation at Akershus University Hospital

Journal: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke

Published: October 24, 2023

Risk Factors for Bleeding in Cancer Patients Treated with Conventional Dose Followed by Low-Dose Apixaban for Venous Thromboembolism.

Risk Factors for Bleeding in Cancer Patients Treated with Conventional Dose Followed by Low-Dose Apixaban for Venous Thromboembolism.

Journal: Thrombosis and haemostasis

Published: October 10, 2023

Arterial events in cancer patients treated with apixaban for venous thrombosis.

Arterial events in cancer patients treated with apixaban for venous thrombosis.

Journal: Thrombosis research

Published: March 13, 2023

Factor Xa inhibitors in the prevention and treatment of venous thromboembolism in cancer patients

Factor Xa inhibitors in the prevention and treatment of venous thromboembolism in cancer patients

Journal: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke

Published: January 19, 2023

"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up": Reply.

"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up": Reply.

Journal: Journal of thrombosis and haemostasis : JTH

Published: April 07, 2022

Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up.

Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up.

Journal: Journal of thrombosis and haemostasis : JTH

Published: December 02, 2021

Cancer and Thrombosis: New Treatments, New Challenges.

Cancer and Thrombosis: New Treatments, New Challenges.

Journal: Medical sciences (Basel, Switzerland)

Published: May 02, 2021

Tissue factor pathway inhibitor and bleeding tendency: can hormonal state explain the differences?

Tissue factor pathway inhibitor and bleeding tendency: can hormonal state explain the differences?

Journal: Blood advances

Published: March 03, 2021

Bias in animal studies of estrogen effects on cardiovascular disease: A systematic review and meta-analysis.

Bias in animal studies of estrogen effects on cardiovascular disease: A systematic review and meta-analysis.

Journal: Research and practice in thrombosis and haemostasis

Published: November 24, 2020

Showing 1-12 of 21

Last Updated: 09/26/2026